Paxil Users Sue GlaxoSmithKline

Users of the antidepressant Paxil have filed suit against GlaxoSmithKline, claiming the world’s second-largest drug maker concealed evidence the drug is addictive.

About 35 people sued the Greenford, England-based company Friday in Los Angeles Superior Court seeking class-action status for claims the second-most-prescribed antidepressant in the U.S. causes dependency and withdrawal symptoms such as shaking, nausea and insomnia.

The users said their doctors, unaware of the alleged withdrawal effects, ordered incorrect treatment such as increased dosages of the drug. The users allege fraud, negligence and breach of warranties, seeking unspecified general and punitive damages.

GlaxoSmithKline’s U.S. officials in Raleigh, N.C., were not available to comment.

The company’s American depositary receipts fell 53 cents to $53.69 on the NYSE.